COMMUNIQUÉS West-GlobeNewswire

Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
15/10/2025
AMX-883 uses Amphista’s Targeted Glue™ technology, inducing degradation of BRD9 through the recruitment of DCAF16, a completely distinct mechanism of action from cereblon- or VHL-based PROTACs. The nomination of AMX-883 [...]
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
15/10/2025
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., Oct. 15, 2025 ( [...]
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
15/10/2025
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading [...]
Communiqué de presse : Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes
15/10/2025
Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes Montpellier, 15 octobre 2025. Sanofi a lancé aujourd'hui à Montpellier un Centre d'Excellence Translationnel, en [...]
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
15/10/2025
A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells PARIS, Oct. 15, 2025 ( [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
15/10/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 15 oct. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
15/10/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE [...]
Vara earns CE mark as the only AI authorized for an independent second read in mammography, and expands in Europe
15/10/2025
BERLIN, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Vara announced today it received a new CE certificate for its new breast-imaging AI – the only on the market allowed to operate as an independent second reader for both [...]
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
15/10/2025
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART’s sustained impact on patient [...]
EyePoint Announces Pricing of Public Offering
15/10/2025
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma
14/10/2025
AUDUBON, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System , a fully comprehensive [...]
EyePoint Announces Proposed Public Offering of Common Stock
14/10/2025
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]
PetMeds® Files Form 10-K for Fiscal 2025
14/10/2025
DELRAY BEACH, Fla., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today filed with the Securities and Exchange Commission (SEC) its [...]
MedCert.us Expands Affordable Licensed Telehealth Medical Marijuana Evaluations Across New York and Virginia
14/10/2025
Licensed medical providers deliver same-day cannabis certifications through secure telehealth consultations for just , ensuring accessible, compliant, and compassionate care under state law. Arlington, Virginia , Oct. [...]
WORK Medical Technology Group LTD Announces Receipt of Delisting Determination Letter from Nasdaq
14/10/2025
Hangzhou, China, Oct. 14, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
14/10/2025
ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The attached two notifications relate to the exercise of vested stock options to purchase ordinary shares previously granted to a director of the Company, and the [...]
Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21
14/10/2025
GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, [...]
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
14/10/2025
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
14/10/2025
– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New preclinical data [...]

Pages